Sionna Therapeutics Faces Securities Probe After Trial Failure

The clinical-stage biopharmaceutical company revealed on August 10, 2026, that the Phase 2a proof-of-concept trial for SION-719 failed to achieve the necessary reduction in sweat chloride levels when administered alongside standard care. This clinical setback wiped out nearly the entire market value of the firm in a single session.

Robbins Geller Rudman & Dowd LLP, a firm specializing in shareholder rights litigation, is now seeking information from investors who incurred losses and potential witnesses familiar with the company's internal disclosures. Attorneys Ken Dolitsky and Michael Albert are leading the inquiry, encouraging affected parties to submit documentation through the firm's legal portal or via direct contact at 800-851-7783.